A highly durable RNAi therapeutic inhibitor of PCSK9

Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R. Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D. Horton, Jorg Taubel, Ashley Brooks, Chamikara Fernando, Robert S. Kauffman, David Kallend, Akshay Vaishnaw, Amy Simon

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9(PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS: The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the γ-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a leastsquares mean reduction of 74.5% from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6% from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8% from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7% from baseline to day 84). CONCLUSIONS: In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months.

Original languageEnglish (US)
Pages (from-to)41-51
Number of pages11
JournalNew England Journal of Medicine
Volume376
Issue number1
DOIs
StatePublished - Jan 5 2017

Fingerprint

RNA Interference
LDL Cholesterol
Least-Squares Analysis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Nasopharyngitis
Musculoskeletal Pain
Subcutaneous Injections
Back Pain
Proprotein Convertase 9
Cough
Headache
Diarrhea
Healthy Volunteers
Placebos
Research Personnel
Lipids
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., ... Simon, A. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. New England Journal of Medicine, 376(1), 41-51. https://doi.org/10.1056/NEJMoa1609243

A highly durable RNAi therapeutic inhibitor of PCSK9. / Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Wijngaard, Peter; Horton, Jay D.; Taubel, Jorg; Brooks, Ashley; Fernando, Chamikara; Kauffman, Robert S.; Kallend, David; Vaishnaw, Akshay; Simon, Amy.

In: New England Journal of Medicine, Vol. 376, No. 1, 05.01.2017, p. 41-51.

Research output: Contribution to journalArticle

Fitzgerald, K, White, S, Borodovsky, A, Bettencourt, BR, Strahs, A, Clausen, V, Wijngaard, P, Horton, JD, Taubel, J, Brooks, A, Fernando, C, Kauffman, RS, Kallend, D, Vaishnaw, A & Simon, A 2017, 'A highly durable RNAi therapeutic inhibitor of PCSK9', New England Journal of Medicine, vol. 376, no. 1, pp. 41-51. https://doi.org/10.1056/NEJMoa1609243
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V et al. A highly durable RNAi therapeutic inhibitor of PCSK9. New England Journal of Medicine. 2017 Jan 5;376(1):41-51. https://doi.org/10.1056/NEJMoa1609243
Fitzgerald, Kevin ; White, Suellen ; Borodovsky, Anna ; Bettencourt, Brian R. ; Strahs, Andrew ; Clausen, Valerie ; Wijngaard, Peter ; Horton, Jay D. ; Taubel, Jorg ; Brooks, Ashley ; Fernando, Chamikara ; Kauffman, Robert S. ; Kallend, David ; Vaishnaw, Akshay ; Simon, Amy. / A highly durable RNAi therapeutic inhibitor of PCSK9. In: New England Journal of Medicine. 2017 ; Vol. 376, No. 1. pp. 41-51.
@article{0ee5f707d4b74a3f8eb241029be0558b,
title = "A highly durable RNAi therapeutic inhibitor of PCSK9",
abstract = "BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9(PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS: The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the γ-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a leastsquares mean reduction of 74.5{\%} from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6{\%} from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8{\%} from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7{\%} from baseline to day 84). CONCLUSIONS: In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months.",
author = "Kevin Fitzgerald and Suellen White and Anna Borodovsky and Bettencourt, {Brian R.} and Andrew Strahs and Valerie Clausen and Peter Wijngaard and Horton, {Jay D.} and Jorg Taubel and Ashley Brooks and Chamikara Fernando and Kauffman, {Robert S.} and David Kallend and Akshay Vaishnaw and Amy Simon",
year = "2017",
month = "1",
day = "5",
doi = "10.1056/NEJMoa1609243",
language = "English (US)",
volume = "376",
pages = "41--51",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "1",

}

TY - JOUR

T1 - A highly durable RNAi therapeutic inhibitor of PCSK9

AU - Fitzgerald, Kevin

AU - White, Suellen

AU - Borodovsky, Anna

AU - Bettencourt, Brian R.

AU - Strahs, Andrew

AU - Clausen, Valerie

AU - Wijngaard, Peter

AU - Horton, Jay D.

AU - Taubel, Jorg

AU - Brooks, Ashley

AU - Fernando, Chamikara

AU - Kauffman, Robert S.

AU - Kallend, David

AU - Vaishnaw, Akshay

AU - Simon, Amy

PY - 2017/1/5

Y1 - 2017/1/5

N2 - BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9(PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS: The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the γ-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a leastsquares mean reduction of 74.5% from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6% from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8% from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7% from baseline to day 84). CONCLUSIONS: In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months.

AB - BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9(PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS: The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the γ-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a leastsquares mean reduction of 74.5% from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6% from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8% from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7% from baseline to day 84). CONCLUSIONS: In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months.

UR - http://www.scopus.com/inward/record.url?scp=85008485863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008485863&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1609243

DO - 10.1056/NEJMoa1609243

M3 - Article

VL - 376

SP - 41

EP - 51

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 1

ER -